AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34306222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent smoking (smoking on some days)
Number of subjects: 981
Study 34306222 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free home/car policies
Number of subjects: 981
Study 34306227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco cessation treatment (prescription for nicotine replacement therapy and referral to the quitline)
Number of subjects: 1007
Study 34306227 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control practices
Number of subjects: 1007
Study 34306677 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylglucosamine
Number of subjects: 50
Study 34307126 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pegylated liposomal doxorubicin (PLD) 35 mg/m²
Number of subjects: 50
Study 34307188 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-lambda 3 and 4 polymorphisms
Number of subjects: 0
Study 34307246 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial steroid treatment, dosage and duration not specified
Number of subjects: 0
Study 34307397 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34307499 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Area Pacing
Number of subjects: 0
Study 34307499 — intervention group
Group type: COMPARATOR
Intervention: Right Ventricular Pacing
Number of subjects: 0
Study 34307504 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Purification Treatment
Number of subjects: 0
Study 34307728 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood culture positivity
Number of subjects: 325
Study 34307728 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to positivity of blood cultures
Number of subjects: 325
Study 34308137 — intervention group
Group type: EXPERIMENTAL
Intervention: Current or former smokers (active or former smokers)
Number of subjects: 5224
Study 34308137 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 5224
Study 34308137 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 5224
Study 34308309 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg DHA per day
Number of subjects: 1100
Study 34308309 — intervention group
Group type: COMPARATOR
Intervention: 200 mg DHA per day
Number of subjects: 1100
Study 34308322 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black participants in the US
Number of subjects: 2102364
Study 34308322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic participants in the US
Number of subjects: 2102364
Study 34308322 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants in the UK
Number of subjects: 2102364
Study 34308322 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian participants in the UK
Number of subjects: 2102364
Study 34308322 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle Eastern participants in the UK
Number of subjects: 2102364
Study 34308366 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline pathogenic and likely pathogenic (P/LP) variants testing
Number of subjects: 751
Study 34308517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 0
Study 34308517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34309015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Number of subjects: 0
Study 34309015 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34309174 — intervention group
Group type: EXPERIMENTAL
Intervention: CD22 CAR T cells
Number of subjects: 3
Study 34309174 — intervention group
Group type: EXPERIMENTAL
Intervention: Heightened inflammatory states
Number of subjects: 3
Study 34309174 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition and prevention of extended inflammation
Number of subjects: 3
Study 34309408 — intervention group
Group type: EXPERIMENTAL
Intervention: Connectome-Based Models
Number of subjects: 0
Study 34309408 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive assessments
Number of subjects: 0
Study 34309636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 230 mg/m2 twice daily
Number of subjects: 58
Study 34309846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cam-FOLFOX4 (Camrelizumab 3 mg/kg iv drip injection every 2 weeks plus FOLFOX4)
Number of subjects: 92
Study 34309846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cam-GEMOX (Camrelizumab 3 mg/kg iv drip injection every 2 weeks plus GEMOX)
Number of subjects: 92
Study 34310027 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-prediction score based on chemotherapy intensity, time since diagnosis, and type of malignancy.
Number of subjects: 238
Study 34310027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antibiotic prophylaxis (4.3 months to prevent one FN with bacteremia, 5.2 months to prevent one FN with SRE).
Number of subjects: 238
Study 34310027 — intervention group
Group type: COMPARATOR
Intervention: Published rules for predicting FN.
Number of subjects: 238
Study 34310102 — intervention group
Group type: EXPERIMENTAL
Intervention: VP2 mRNA expression measured by real-time polymerase chain reaction
Number of subjects: 102
Study 34310102 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular TCMR classifier
Number of subjects: 102
Study 34310102 — intervention group
Group type: EXPERIMENTAL
Intervention: BKN probability classifier
Number of subjects: 102
Study 34310102 — intervention group
Group type: COMPARATOR
Intervention: Histological assessment of TCMR
Number of subjects: 102
Study 34310102 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of tubulitis and inflammation
Number of subjects: 102
Study 34310218 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 0
Study 34310218 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 34310436 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical resolution (total bilirubin [TB] ≤1 mg/dL and ALT <35 U/L)
Number of subjects: 94
Study 34310436 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resolution (TB >1 mg/dL and/or ALT >35 U/L)
Number of subjects: 94
Study 34310436 — intervention group
Group type: EXPERIMENTAL
Intervention: Exited healthy (resolved disease per study site report but without documented biochemical resolution)
Number of subjects: 94
Study 34310436 — intervention group
Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 94
Study 34310436 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplant
Number of subjects: 94
Study 34310436 — intervention group
Group type: EXPERIMENTAL
Intervention: GGT <100 U/L at baseline
Number of subjects: 94
Study 34310498 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Cycling (PC) training program consisting of 30 bouts of 4 s at an all-out intensity, 3 times a week for 8 weeks
Number of subjects: 11
Study 34310498 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Cycling (PC) training program
Number of subjects: 11
Study 34310745 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel
Number of subjects: 0
Study 34310745 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 0
Study 34310745 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel
Number of subjects: 0
Study 34310835 — intervention group
Group type: EXPERIMENTAL
Intervention: One metastasectomy
Number of subjects: 220
Study 34310835 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple local interventions
Number of subjects: 220
Study 34310835 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (1 to 5 courses)
Number of subjects: 220
Study 34310835 — intervention group
Group type: COMPARATOR
Intervention: No metastasectomy
Number of subjects: 220
Study 34310871 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive NAVA
Number of subjects: 18
Study 34310871 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive NAVA
Number of subjects: 18
Study 34310871 — intervention group
Group type: COMPARATOR
Intervention: NAVA (both invasive and noninvasive)
Number of subjects: 18
Study 34311211 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HER2 expression (IHC 1+, or IHC 2+/ISH negative)
Number of subjects: 0
Study 34311211 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC 2+
Number of subjects: 0
Study 34311211 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HER2 expression
Number of subjects: 0
Study 34311211 — intervention group
Group type: COMPARATOR
Intervention: No HER2 expression (IHC score 0)
Number of subjects: 0
Study 34311566 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire stent-retriever
Number of subjects: 984
Study 34311567 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 801
Study 34311567 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 801
Study 34311567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent patients
Number of subjects: 801
Study 34311567 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent patients
Number of subjects: 801
Study 34311765 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for addiction services referrals
Number of subjects: 305
Study 34311765 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for syringe service programs (SSP) referrals
Number of subjects: 305
Study 34311765 — intervention group
Group type: COMPARATOR
Intervention: Support for addiction services based on district assignment
Number of subjects: 305
Study 34311765 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in methadone programs reducing crime
Number of subjects: 305
Study 34311765 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for SSP based on age
Number of subjects: 305
Study 34311765 — intervention group
Group type: COMPARATOR
Intervention: Support for SSP based on district assignment
Number of subjects: 305
Study 34311765 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in methadone programs reducing crime for SSP support
Number of subjects: 305
Study 34311765 — intervention group
Group type: COMPARATOR
Intervention: Belief in SSPs increasing needlestick injury risk
Number of subjects: 305
Study 34311780 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy combinations with personalized vaccines, checkpoint inhibitors, targeted therapies, multikinase inhibitors, chemotherapies, and radiation
Number of subjects: 0
Study 34312155 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth GupShup Potli (GSP) audio recordings
Number of subjects: 4608
Study 34312155 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC paper-based tools
Number of subjects: 4608
Study 34312155 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed women)
Number of subjects: 4608
Study 34312201 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in children
Number of subjects: 2585
Study 34312201 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in grades 1-2
Number of subjects: 2585
Study 34312201 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in grades 4-5
Number of subjects: 2585
Study 34312201 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in grades 7-8
Number of subjects: 2585
Study 34312201 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-compatible symptoms reported by children
Number of subjects: 2585
Study 34312201 — intervention group
Group type: COMPARATOR
Intervention: Comparison of seroprevalence in children and adults
Number of subjects: 2585
Study 34312201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of confirmed SARS-CoV-2 cumulative incidence-to-seropositive cases
Number of subjects: 2585
Study 34312211 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular ultrasonography (NMUS)
Number of subjects: 37
Study 34312211 — intervention group
Group type: COMPARATOR
Intervention: Nerve conduction study (NCS)
Number of subjects: 37
Study 34312462 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of mb-IL21 ex vivo expanded donor-derived NK cells
Number of subjects: 25
Study 34312483 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-GITR neutralizing antibodies
Number of subjects: 73
Study 34312483 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiation therapy
Number of subjects: 73
Study 34312544 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory antigen-specific CD8 T cells
Number of subjects: 0
Study 34312544 — intervention group
Group type: COMPARATOR
Intervention: Exhausted antigen-specific CD8 T cells
Number of subjects: 0
Study 34312556 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T cells with dual targeting of CD19 and CD22
Number of subjects: 16
Study 34312556 — intervention group
Group type: COMPARATOR
Intervention: CAR19 treatment
Number of subjects: 16
Study 34312616 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly voluntary screening for SARS-CoV-2 with a high sensitivity molecular-based saliva test
Number of subjects: 475
Study 34312616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitigation strategies including higher than expected student mask compliance, reduced room capacity, and phased reopening
Number of subjects: 475
Study 34312616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitigation strategies
Number of subjects: 475
Study 34312724 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 Lockdown (P20)
Number of subjects: 123
Study 34312724 — intervention group
Group type: COMPARATOR
Intervention: Pre-COVID period (P19)
Number of subjects: 123
Study 34312724 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in ED presentation
Number of subjects: 123
Study 34312919 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch saphenous veins in on-pump CABG
Number of subjects: 56
Study 34312919 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch saphenous veins in off-pump CABG
Number of subjects: 56
Study 34312919 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal thoracic arteries
Number of subjects: 56
Study 34312919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein grafts to left anterior descending and diagonal arteries
Number of subjects: 56
Study 34312919 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch saphenous veins in right coronary territory (off-pump)
Number of subjects: 56
Study 34313474 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar no-touch radiofrequency ablation (RFA)
Number of subjects: 0
Study 34313599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyson air purifiers (Dyson Pure Cool)
Number of subjects: 50
Study 34313599 — intervention group
Group type: COMPARATOR
Intervention: Placebo Dyson filters
Number of subjects: 50
Study 34313611 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 909
Study 34313752 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGIT instrument for CGE-DC
Number of subjects: 227
Study 34313752 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGIT instrument for clinician's therapeutic decision
Number of subjects: 227
Study 34313752 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGIT instrument for international guidelines
Number of subjects: 227
Study 34313752 — intervention group
Group type: COMPARATOR
Intervention: CGE-DC non-controlled acromegaly
Number of subjects: 227
Study 34313764 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models using nonmodifiable variables
Number of subjects: 313
Study 34313764 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models using directly modifiable variables
Number of subjects: 313
Study 34313764 — intervention group
Group type: COMPARATOR
Intervention: Multivariate linear regression using directly modifiable variables
Number of subjects: 313
Study 34313764 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly modifiable features (dietary factors)
Number of subjects: 313
Study 34313764 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stool pH
Number of subjects: 313
Study 34313764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmodifiable factors (age, sex, ethnicity)
Number of subjects: 313
Study 34314241 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolieve Transurethral Thermodilatation
Number of subjects: 0
Study 34314285 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict social distancing protocols (T1)
Number of subjects: 10061
Study 34314285 — intervention group
Group type: COMPARATOR
Intervention: Discontinued social distancing protocols (T2)
Number of subjects: 10061
Study 34314285 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 10061
Study 34314285 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher health anxiety
Number of subjects: 10061
Study 34314285 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of maladaptive coping strategies and negative metacognitive beliefs
Number of subjects: 10061
Study 34314483 — intervention group
Group type: EXPERIMENTAL
Intervention: Danicopan (100 to 200 mg thrice daily)
Number of subjects: 12
Study 34315238 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Takotsubo syndrome and atrial fibrillation (AF)
Number of subjects: 1584
Study 34315238 — intervention group
Group type: COMPARATOR
Intervention: Patients with Takotsubo syndrome without atrial fibrillation (AF)
Number of subjects: 1584
Study 34315415 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in screening for blood-borne viral infections (BBV) using finger prick testing and risk factor assessment via questionnaire.
Number of subjects: 886
Study 34315419 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) 266 mg
Number of subjects: 20
Study 34315432 — intervention group
Group type: EXPERIMENTAL
Intervention: ECV-guided LGE analysis
Number of subjects: 110
Study 34315432 — intervention group
Group type: COMPARATOR
Intervention: Manual LGE assessment
Number of subjects: 110
Study 34315432 — intervention group
Group type: EXPERIMENTAL
Intervention: ECV-guided analysis
Number of subjects: 110
Study 34315519 — intervention group
Group type: EXPERIMENTAL
Intervention: Low burden group (definition 1)
Number of subjects: 318
Study 34315519 — intervention group
Group type: EXPERIMENTAL
Intervention: Low burden group (definition 2)
Number of subjects: 318
Study 34315519 — intervention group
Group type: EXPERIMENTAL
Intervention: Low burden group (definition 3)
Number of subjects: 318
Study 34315519 — intervention group
Group type: COMPARATOR
Intervention: Aβ-negative group
Number of subjects: 318
Study 34315540 — intervention group
Group type: EXPERIMENTAL
Intervention: External facilitation (EF)
Number of subjects: 6
Study 34315767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilpacimab (3.75 mg/kg)
Number of subjects: 55
Study 34315767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilpacimab (various doses 1.25-7.5 mg/kg)
Number of subjects: 55
Study 34315767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilpacimab (various doses)
Number of subjects: 55
Study 34315793 — intervention group
Group type: COMPARATOR
Intervention: Ripasudil 0.4% eye drops administered once daily for 1 week, then two times per day for 2 weeks in phase I, and two times per day for 12 weeks in phase II.
Number of subjects: 0
Study 34315793 — intervention group
Group type: COMPARATOR
Intervention: Ripasudil 0.4% eye drops
Number of subjects: 0
Study 34315821 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab added to standard treatment
Number of subjects: 43
Study 34315821 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 43
Study 34315890 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related amenorrhea (TRA)
Number of subjects: 789
Study 34315890 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumed menses after TRA
Number of subjects: 789
Study 34316356 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Number of subjects: 0
Study 34316356 — intervention group
Group type: COMPARATOR
Intervention: No physical rehabilitation
Number of subjects: 0
Study 34316644 — intervention group
Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA
Number of subjects: 0
Study 34317072 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 34318292 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34319245 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring System (RPMS) for 3 months; includes a tablet, weight scale, and pedometer providing daily educational content, weekly weigh-ins.
Number of subjects: 45
Study 34319249 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) engagement
Number of subjects: 55
Study 34319249 — intervention group
Group type: EXPERIMENTAL
Intervention: Child life specialist support
Number of subjects: 55
Study 34319249 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no standardized support)
Number of subjects: 55
Study 34319359 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Behavioral Science Messages
Number of subjects: 0
Study 34319359 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34319435 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin and 5-fluorouracil (TPF) induction chemotherapy
Number of subjects: 47
Study 34319435 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after TPF chemotherapy
Number of subjects: 47
Study 34319435 — intervention group
Group type: COMPARATOR
Intervention: Radical concurrent chemoradiotherapy after TPF chemotherapy
Number of subjects: 47
Study 34319435 — intervention group
Group type: COMPARATOR
Intervention: TPF chemotherapy alone
Number of subjects: 47
Study 34319564 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAC 3.6 g
Number of subjects: 46
Study 34319564 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (positive control)
Number of subjects: 46
Study 34319564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 34319808 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34319865 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV/PCV13
Number of subjects: 0
Study 34319865 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study 34319865 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 0